Treatment of Patients With Type 2 Diabetes With an Interleukin-1 Antagonist
Aim: To investigate the therapeutic potential of IL-1Ra in type 2 diabetes.
Rationale: Since the major defect leading to a decrease in b-cell mass in type 2 diabetes is increased apoptosis, therapeutic approaches designed to arrest apoptosis could be a significant new development in its management. This approach might actually reverse the disease to a degree rather than just palliate glycemia. Based on current thinking, treatment with IL-1Ra appears as a promising approach. The prospected effect is blocking of the IL-1b-mediated glucotoxicity and thereby to prevent the decline in b-cell mass, together with a rapid restoration of b-cell function. FDA approval for IL-1Ra in the treatment of rheumatoid arthritis occurred based on a favourable tolerability profile.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Primary Purpose: Treatment
|Official Title:||Phase 2 Study of IL-1Ra in Patients With Type 2 Diabetes|
- Insulin requirement
- Stimulated C peptide and insulin
- Fasting plasma glucose (FPG)
- Serum cytokine levels, CRP
- Insulin secretion and Insulin-sensitivity index derived from an OGTT with insulin and glucose measurements.
- In a subgroup of patients, insulin-sensitivity assessed by clamp techniques
- Insulin signaling- and cytokine- gene expression profiles derived from muscle and fat biopsy samples.
|Study Start Date:||April 2004|
|Estimated Study Completion Date:||March 2006|
Methodology: This will be a two-centre (University Hospital, Zurich, Switzerland and Steno Diabetes Center, Gentofte, Denmark) study. 72 patients will be randomised according to a double-blind, placebo-controlled protocol in which half of the patients are treated with IL-1Ra, the other half with saline. The treatment period will last 13 weeks. This time-period should be sufficient for reversal of functional glucotoxicity and feasible in terms of patient compliance. Whether 13 weeks of treatment will be sufficient to make significant changes in b-cell mass in unpredictable. However, blocking b-cell apoptosis, while new islet formation and b-cell replication are normal, may initiate enlargement of b-cell mass, which may progress beyond the treatment period. Patient evaluation will be performed at start and after 4, 13, 26, 39 and 52 weeks. Following 13 weeks, patients with a fasting plasma glucose levels > 8 mM or with a glycosylated hemoglobin level (HbA1c) > 8% will be treated with insulin. Insulin treatment will not be initiated earlier to avoid interference with possible effects of insulin on primary outcome in the period where the largest effect of IL-1Ra are expected. To assess effects of IL-1Ra on insulin sensitivity, a subset of 40 patients (20 IL-1Ra- and 20 placebo-treated) will undergo an euglycemic-hyperinsulinemic clamp as well as a muscle and fat biopsy at start and after the end of treatment (13 weeks). The Ethics Committee of both centres have already approved the procedure.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00303394
|Steno Diabetes Center|
|Gentofte, Copenhagen, Denmark, 2280|
|University Hospital of Zurich, Division of Endocrinology and Diabetes|
|Zurich, Switzerland, 8091|
|Study Chair:||Marc Y Donath, MD||University of Zurich|